A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.

Kenichi FurihataHanaka MimuraShweta Urva Tomonori Oura Shweta UrvaTakeshi Imaoka

Published in: Diabetes, obesity & metabolism (2021)

All tirzepatide doses were well tolerated. The safety, tolerability, PK, and PD profiles of tirzepatide support further evaluation of once-weekly dosing in Japanese people with T2D.

Keyphrases

open label
pulmonary artery
clinical trial
coronary artery
pulmonary hypertension